
    
      The duration of the study for a patient will include a period for inclusion of up to 3 weeks.
      The patients may continue treatment up to a maximum of 6 cycles or until disease progression,
      unacceptable toxicity or consent withdrawal, followed by a minimum of 30-day follow-up after
      the last study treatment administration.

      Patients will be followed for at least 30 days after the last administration of study
      treatment for safety purpose. In case of study treatment discontinuation without disease
      progression, efficacy data will be collected every 6 weeks until disease progression, death
      or end of study whatever comes first. After disease progression, the patient will be
      followed-up every 12 weeks (3 months) for overall survival (OS) until death or end of study
      whatever comes first.

      The end of the study will be one year after the first dose of the last treated patient.
    
  